IgA EGFR antibodies mediate tumour killing in vivo. - Wikidata - wikimedia - TriplyDB

IgA EGFR antibodies mediate tumour killing in vivo.

IgA EGFR antibodies mediate tumour killing in vivo.

http://www.wikidata.org/entity/Q39114924

about

Influence of immunoglobulin isotype on therapeutic antibody function Neutrophils in Cancer: Two Sides of the Same Coin Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy IgE immunotherapy against cancer Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.Exploring Site-Specific N-Glycosylation of HEK293 and Plant-Produced Human IgA Isotypes.Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).The era of the immunoglobulin A Fc receptor FcαRI; its function and potential as target in disease.Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.Exploitation of the Polymeric Immunoglobulin Receptor for Antibody Targeting to Renal Cyst Lumens in Polycystic Kidney Disease Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA.Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting Enhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors.Immunoglobulin A: magic bullet or Trojan horse?Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody.Transient Glyco-Engineering to Produce Recombinant IgA1 with Defined N- and O-Glycans in Plants Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy.Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA Antibody Isotypes for Tumor Immunotherapy.Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo.CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy.An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations.

P2860

Q26772080-869E51E7-E899-45E1-8D1C-4323FF0EB101 Q26773072-20BC8D69-63AE-4231-A2A5-97513D632EEC Q26993238-75205725-1CC6-4A16-88BF-AC61666AACC6 Q28081223-AF030C90-32E9-4180-80D5-EAFACAF89CD5 Q33889191-2C1FEAFC-292B-4E0F-8002-89AF98B1E877 Q33891585-88EB8E63-08BC-4FB3-8FD7-A6E5546EC9E7 Q34000700-14622ECA-4453-4FC1-87E6-0CD80B462FEF Q34499286-8C142372-CC20-43F1-A161-C3EFB61A46D1 Q35569901-9409901F-F111-4E14-88F6-D6214C321A1C Q35860685-309B6CF6-15E3-4E37-B43B-603ABB6F0F52 Q36216363-43789E53-9D09-46FD-A2DD-30B81D6531AE Q37138274-ECB1A60E-117C-42C3-9C50-9D394B948983 Q37138332-1E0C1E50-2FC3-4A46-901F-500599D1AFF1 Q37593675-E0F1EF8C-AE53-496C-9B41-6139648B2E36 Q38778020-DECFF45E-B630-4963-9B36-027DC7CFD0BC Q39027573-CEF09C7A-D035-491F-B247-512EA53591B1 Q40011916-44932EED-BAF9-4F5E-A845-3B2D24F400DB Q41704272-2346C8F8-4773-48D4-BFE6-4FBA082429BC Q42557137-83F46A11-B24C-44D7-81CD-39CC21A687CA Q42660171-84FFC645-B636-4770-A6B2-8E36033B8FCA Q48223734-E46AE476-6FD8-46ED-8538-EB60714AC2AD Q52648924-EA31DFA8-4C76-4C05-B0E4-4F4692FB8B3B Q52731744-D7355D83-7933-42C8-A952-B9E33E63063C Q55439903-1E2E8EFF-CC9C-4D0B-9EE7-B6088D3C3AE0

P2860

IgA EGFR antibodies mediate tumour killing in vivo.

http://www.wikidata.org/entity/Q39114924

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

IgA EGFR antibodies mediate tumour killing in vivo.

@en

IgA EGFR antibodies mediate tumour killing in vivo.

@nl

type

label

IgA EGFR antibodies mediate tumour killing in vivo.

@en

IgA EGFR antibodies mediate tumour killing in vivo.

@nl

prefLabel

IgA EGFR antibodies mediate tumour killing in vivo.

@en

IgA EGFR antibodies mediate tumour killing in vivo.

@nl

P1433

Q39114924-5AF063D9-C6A9-4B3D-8274-8F32BA9761DA

P1476

Q39114924-04A7D1AC-FF3F-4E13-9303-76E08AD35931

P2093

Q39114924-0C983088-A109-41B3-9FD4-698E0587BA94

Q39114924-1154C77B-2CC2-4EB9-9AA1-0F0151ECC2CE

Q39114924-2116028D-A463-41BD-B689-5C49FE382AAB

Q39114924-2189C7A4-1BBC-4D57-871B-B05995C819DD

Q39114924-3D8B66B5-921A-48FB-96D3-A64937F1E7DC

Q39114924-3FEA424E-C8EC-43B0-AE7C-36CF1E4D8387

Q39114924-55F5658A-57F7-4F5C-BE10-85CC1CB6049D

Q39114924-57ACACBA-E19D-4B3F-A40D-C2CD41C780B0

Q39114924-5D95AB38-A465-49E6-8A8B-D0F9CDE868C8

Q39114924-78AFE9A1-0D70-4FCA-BAFF-4A4A6CD02A77

P2860

Q39114924-0231DCE8-50AB-40E1-9359-05C210D698DE

Q39114924-0C8F6D22-2FD8-4E32-B0CB-1DBBD1B164CC

Q39114924-0EAF676F-9F9D-4DEF-A071-F07862B813C6

Q39114924-1714DCC3-D851-4A59-931F-3A77927514F7

Q39114924-19A8F879-1D8B-4633-8092-74DCB6E0412E

Q39114924-2AB19D72-9E1B-45C1-AFDE-DF98EE5BC487

Q39114924-30FD3BB2-2D91-485B-97FE-316A11CBF66D

Q39114924-34648183-B850-4622-AD25-CB53365F6AD5

Q39114924-35C5B492-867A-4355-9EEE-0BDE21A057C3

Q39114924-37FF293D-DB5E-4D3B-9204-C87145350F5D

P304

Q39114924-4790BF99-43A7-4939-BE8B-3B1BAC3F5180

P31

Q39114924-7883C0F4-DAFD-4844-A86C-9919519D12D4

P356

Q39114924-588BAB5F-8B3B-4BC1-8BBE-D6385DFAF168

P433

Q39114924-CD4E50C2-DB3F-43D8-B781-536517187A6B

P478

Q39114924-F9E25661-8697-473B-9EDC-13946A96074D

P50

Q39114924-512EA34C-C87F-4425-8468-C53A472699C8

Q39114924-70C983CF-3DEC-4DC1-8202-F8F58E2642A1

P577

Q39114924-DFC8F4C7-37C8-4D0E-A8AE-FD5DC51A7912

P5875

Q39114924-FC48F171-9F23-4CAB-8260-05AF5B0472E0

P698

Q39114924-6F431D1A-32DB-4C16-A509-E739417783B3

P921

Q39114924-2638AA88-5A7F-4758-BC3D-897413A8BF92

P932

Q39114924-CBE88F71-DF9C-480A-BD83-C58995476C32

P356

P1433

EMBO Molecular Medicine

P1476

IgA EGFR antibodies mediate tumour killing in vivo.

@en

P2093

Geert van Tetering

http://www.w3.org/2001/XMLSchema#string

Jan G J van de Winkel

http://www.w3.org/2001/XMLSchema#string

Jeanette H W Leusen

http://www.w3.org/2001/XMLSchema#string

Johannes Hendrik Marco Jansen

http://www.w3.org/2001/XMLSchema#string

Li Phing Liew

http://www.w3.org/2001/XMLSchema#string

Louis Boon

http://www.w3.org/2001/XMLSchema#string

Louise Royle

http://www.w3.org/2001/XMLSchema#string

Maaike Nederend

http://www.w3.org/2001/XMLSchema#string

Matthias Peipp

http://www.w3.org/2001/XMLSchema#string

Michael Dechant

http://www.w3.org/2001/XMLSchema#string

P2860

FcalphaRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity

The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

IgA Fc receptors

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

Human serum IgA1 is substituted with up to six O-glycans as shown by matrix assisted laser desorption ionisation time-of-flight mass spectrometry.

Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo.

The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity.

Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation.

Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.

P304

1213-1226

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/EMMM.201201929

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Paul Whi Parren

Nico van Rooijen

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255689860

http://www.w3.org/2001/XMLSchema#string

P698

23918228

http://www.w3.org/2001/XMLSchema#string

P921

P932

3944462

http://www.w3.org/2001/XMLSchema#string